209 related articles for article (PubMed ID: 31406196)
21. Chromosome 17 polysomy: correlation with histological parameters and HER2NEU gene amplification.
Orsaria M; Khelifa S; Buza N; Kamath A; Hui P
J Clin Pathol; 2013 Dec; 66(12):1070-5. PubMed ID: 23908451
[TBL] [Abstract][Full Text] [Related]
22. Unraveling the chromosome 17 patterns of FISH in interphase nuclei: an in-depth analysis of the HER2 amplicon and chromosome 17 centromere by karyotyping, FISH and M-FISH in breast cancer cells.
Rondón-Lagos M; Verdun Di Cantogno L; Rangel N; Mele T; Ramírez-Clavijo SR; Scagliotti G; Marchiò C; Sapino A
BMC Cancer; 2014 Dec; 14():922. PubMed ID: 25481507
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of centromere 17 copy number gain in breast cancer depends on breast cancer subtype.
Lee K; Jang MH; Chung YR; Lee Y; Kang E; Kim SW; Kim YJ; Kim JH; Kim IA; Park SY
Hum Pathol; 2017 Mar; 61():111-120. PubMed ID: 27989787
[TBL] [Abstract][Full Text] [Related]
24. Effect of high copy number of HER2 associated with polysomy 17 on HER2 protein expression in invasive breast carcinoma.
Shah SS; Wang Y; Tull J; Zhang S
Diagn Mol Pathol; 2009 Mar; 18(1):30-3. PubMed ID: 19214111
[TBL] [Abstract][Full Text] [Related]
25. The frequency and clinical significance of centromere enumeration probe 17 alterations in human epidermal growth factor receptor 2 immunohistochemistry-equivocal invasive breast cancer.
Katayama A; Starczynski J; Toss MS; Shaaban AM; Provenzano E; Quinn CM; Callagy G; Purdie CA; Millican-Slater R; Purnell D; Chagla L; Oyama T; Pinder SE; Chan S; Ellis I; Lee AHS; Rakha EA
Histopathology; 2022 Oct; 81(4):511-519. PubMed ID: 35879836
[TBL] [Abstract][Full Text] [Related]
26. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing.
Vanden Bempt I; Van Loo P; Drijkoningen M; Neven P; Smeets A; Christiaens MR; Paridaens R; De Wolf-Peeters C
J Clin Oncol; 2008 Oct; 26(30):4869-74. PubMed ID: 18794552
[TBL] [Abstract][Full Text] [Related]
27. Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity.
Gunn S; Yeh IT; Lytvak I; Tirtorahardjo B; Dzidic N; Zadeh S; Kim J; McCaskill C; Lim L; Gorre M; Mohammed M
BMC Cancer; 2010 Jul; 10():396. PubMed ID: 20667129
[TBL] [Abstract][Full Text] [Related]
28. Utility of Alternate, Noncentromeric Chromosome 17 Reference Probe for Human Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization Testing in Breast Cancer Cases.
Pai T; Shet T; Patil A; Shetty O; Singh A; Desai SB
Arch Pathol Lab Med; 2018 May; 142(5):626-633. PubMed ID: 29384691
[TBL] [Abstract][Full Text] [Related]
29. Impact of polysomy 17 on HER2 testing of invasive breast cancer patients.
Liu Y; Ma L; Liu D; Yang Z; Yang C; Hu Z; Chen W; Yang Z; Chen S; Zhang Z
Int J Clin Exp Pathol; 2014; 7(1):163-73. PubMed ID: 24427336
[TBL] [Abstract][Full Text] [Related]
30. The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study.
Downs-Kelly E; Yoder BJ; Stoler M; Tubbs RR; Skacel M; Grogan T; Roche P; Hicks DG
Am J Surg Pathol; 2005 Sep; 29(9):1221-7. PubMed ID: 16096413
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic strategies in male breast cancer: clinical implications of chromosome 17 gene alterations and molecular subtypes.
Schildhaus HU; Schroeder L; Merkelbach-Bruse S; Binot E; Büttner R; Kuhn W; Rudlowski C
Breast; 2013 Dec; 22(6):1066-71. PubMed ID: 24080492
[TBL] [Abstract][Full Text] [Related]
32. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
[TBL] [Abstract][Full Text] [Related]
33. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
Donaldson AR; Shetty S; Wang Z; Rivera CL; Portier BP; Budd GT; Downs-Kelly E; Lanigan CP; Calhoun BC
Cancer; 2017 Jun; 123(12):2230-2239. PubMed ID: 28192599
[TBL] [Abstract][Full Text] [Related]
34. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
[TBL] [Abstract][Full Text] [Related]
35. [Evaluation of HER2 gene expression status in breast cancer by fluorescence in-situ hybridization].
Zeng X; Zhao DC; Zhou WX; Wu SF; Liang ZY; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2005 Nov; 34(11):701-5. PubMed ID: 16536311
[TBL] [Abstract][Full Text] [Related]
36. Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer.
Zhu X; Lu Y; Lu H; Yang W; Tu X; Cai X; Zhou X
Hum Pathol; 2011 Oct; 42(10):1499-504. PubMed ID: 21676436
[TBL] [Abstract][Full Text] [Related]
37. Comparative Pathologic Analysis of Breast Cancers Classified as HER2/neu-Amplified by FISH Using a Standard HER2/CEP17 Dual Probe and an Alternative Chromosome 17 Control Probe.
Zare S; Lin L; Alghamdi AG; Daehne S; Roma AA; Hasteh F; Dell'Aquila M; Fadare O
Am J Surg Pathol; 2018 Sep; 42(9):1208-1215. PubMed ID: 29923906
[TBL] [Abstract][Full Text] [Related]
38. [Evaluation and indication of human epithelial growth factor receptor 2 status in breast carcinoma with amplified chromosome].
Zhang S; Wang Y; Guo ZM; Zhang H; Xu L; Liu YH; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Oct; 46(5):686-90. PubMed ID: 25331387
[TBL] [Abstract][Full Text] [Related]
39. Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer.
Dal Lago L; Durbecq V; Desmedt C; Salgado R; Verjat T; Lespagnard L; Ma Y; Veys I; Di Leo A; Sotiriou C; Piccart M; Larsimont D
Mol Cancer Ther; 2006 Oct; 5(10):2572-9. PubMed ID: 17041102
[TBL] [Abstract][Full Text] [Related]
40. Isolated CEP17 Copy Number Gain in Invasive Breast Cancer Results in a "Reverse" Amplification Status.
Van Bockstal MR; Dubois D; Talpe S; Galant C
Int J Surg Pathol; 2021 Feb; 29(1):76-77. PubMed ID: 32131665
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
